CYAD-101

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameCYAD-101

Drug Alias NameTIM8-CYAD-01CYAD-101

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionNKG2D ligands modulators

TargetsNKG2D ligands

Therapy Area/IndicationsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCelyad Oncology SA

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCelyad Oncology SA

Active IndicationsN/A

Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeN/A